Navigation Links
Scioderm's Investigational New Drug (IND) Application for SD-101 for Treatment of Epidermolysis Bullosa (EB) Allowed by the FDA
Date:2/13/2013

to the clinic," said Brett Kopelan , Executive Director of the Dystrophic EB Research Association of America (DebRA ) and father to a 5-year-old girl with recessive dystrophic EB.  "I look forward to working with Scioderm as they work towards improving the quality of life of those with EB by targeting the chronic wounds that are the hallmark of this disease."

About SD-101

SD-101 is a topical cream that has previously demonstrated potential to provide improvement in treating the severe skin effects seen in patients across all EB subtypes.  An open- label study was conducted previously in children with either Simplex, Recessive Dystrophic (RDEB), or Junctional EB.  The primary outcome measurements were assessment of target wound reduction and closure, and reduction in body surface area (BSA) coverage of lesions and erosions.  In the clinical trial, SD-101 application resulted in complete closure of 88% of target chronic lesions within one month, in addition to a 57% reduction in BSA coverage of lesions and erosions after 3 months of daily treatment.   SD-101 was well tolerated by the children, with daily administration up to 3 months.

About Scioderm

Scioderm is a privately held, clinical-stage pharmaceutical company focused on developing topical products to address critical medical needs in the treatment of chronic skin diseases.  Additional information about Scioderm can be found at www.sderm.com

Company Contact:

Robert Coull
Chief Operating Officer
robert.coull@sderm.com  
(917) 345-2504   

Forward-Looking Statements 

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, i
'/>"/>

SOURCE Scioderm
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
2. Data from Study of Elderly Depressed Patients are Reported for Investigational Compound Lu AA21004 on Symptoms of Major Depressive Disorder (MDD)
3. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Abbott Presents Results of Clinical Studies Evaluating Its Investigational Treatment for Advanced Parkinsons Disease
8. Results For Phase 2b Trial Of Unique Investigational Cell-Based Therapy In Venous Leg Ulcers Published In The Lancet
9. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
10. Clinical Study With Investigational Cream Aims To Help Women Who Experience Painful Sex
11. Omeros Files Investigational New Drug Application for Lead Compound in PDE10 Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014   Vestagen Technical Textiles, ... patient experience at hospitals. The myComfort™ line of patient ... barrier fabric that is fluid repellant, breathable and in ... the growth of bacteria on the fabric i . ... plays in the chain of transmission. We want myComfort ...
(Date:9/16/2014)... 2014 The Lupus Foundation of America and ... today released results from UNVEIL: understanding the impact of ... lupus journey and the challenges not only for those ... UNVEIL study, which involved over 1,000 people with lupus ... on all aspects of life including family, work, finances, ...
(Date:9/16/2014)... , Sept. 16, 2014 Imprimis Pharmaceuticals, Inc. ... dedicated to delivering high quality and novel medicines to ... Chief Executive Officer Mark Baum will be ... Alpha Select Conference in New York City.  Mr. Baum ... Go Dropless™ campaign in ophthalmology. The presentation is scheduled ...
Breaking Medicine Technology:New Vestagen Patient Garments Aim to Minimize Pathogen Transmission Inside Hospitals 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 3"UNVEIL" Survey Reveals a Life Interrupted by Lupus 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 5Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 2Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 3Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 4
(Date:9/16/2014)... Aspen Advisors, a U.S.-based healthcare IT consulting firm, ... high morale and collaborative culture in the ... Work For 2014.” Consulting magazine publishes the popular ... participating across all major industries, representing more than 350 ... firms were ranked in six categories - firm culture, ...
(Date:9/16/2014)... and radiation therapy as part of breast conservation ... with hormone-receptor positive (HR+) invasive breast cancer. A ... Center, however, shows that combination may not be ... , The results, which Fox Chase researchers ... 56th Annual Meeting on Sunday, September 14, suggest ...
(Date:9/16/2014)... Seven heroes who have dramatically improved ... honored in New York City on November 6 by ... global recognition and funding program that honors individuals serving ... as the “Nobel Prize for Child Advocates,” this year’s ... that benefit children in countries around the world dealing ...
(Date:9/16/2014)... As part of its Latinos Living ... (LULAC) will host the second annual health festival in ... free health screenings for osteoporosis, HIV, and high blood ... cholesterol levels as well as bone marrow typing. In ... 6 years old , The event will also feature ...
(Date:9/16/2014)... HealthDay Reporter TUESDAY, ... U.S. cancer survivors are alive today, compared to just ... Research reported Tuesday. These individuals amount to 4 ... of childhood cancer, according to the association,s annual progress ... and treatment of cancer and details some of the ...
Breaking Medicine News(10 mins):Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 2Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 3Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 3Health News:World of Children® Award Announces 2014 Honorees 2Health News:World of Children® Award Announces 2014 Honorees 3Health News:World of Children® Award Announces 2014 Honorees 4Health News:World of Children® Award Announces 2014 Honorees 5Health News:World of Children® Award Announces 2014 Honorees 6Health News:World of Children® Award Announces 2014 Honorees 7Health News:World of Children® Award Announces 2014 Honorees 8Health News:LULAC Hosts Second Annual Latinos Living Healthy Feria de Salud in Los Angeles 2Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 2Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 3Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 4
... that combines 2 medications , , SUNDAY, March 30 (HealthDay News) ... make sense of a trial showing that a drug can ... apparent benefit to people at high risk of heart attack ... well-known statin -- simvastatin -- with ezetimibe, which also lowers ...
... use with angioplasty following a heart attack, the anticoagulants ... measures within 90 minutes after the procedure, while patients ... a lower risk of major adverse cardiac events within ... to a JAMA study being released early online March ...
... risk and don,t increase mortality probability , , SUNDAY, March ... placed in diseased coronary arteries to keep them open, ... patients, new research shows. , In the largest study ... the drug in question retards the growth of arterial ...
... to Join Nation,s Largest RN ... Organization, ... registered nurses to have a stronger voice to speak,out for patients and ... to win union collective bargaining,rights., RNs at Cypress Fairbanks Medical Center ...
... deaths could be avoided with lifestyle changes, experts say, ... that could cut cancer deaths in half. , Well, ... American Cancer Society report that said as many as ... lifestyle changes, such as quitting smoking, maintaining a healthy ...
... mice was important protective mechanism, researchers say , , FRIDAY, March ... a critical role in protecting the heart during a heart ... It was already known that Gi increased activity in a ... helping the heart adapt to damage or if it actually ...
Cached Medicine News:Health News:Cholesterol Drug Controversy Continues 2Health News:Cholesterol Drug Controversy Continues 3Health News:Comparison of anticoagulants for angioplasty show similar outcomes 2Health News:Drug-Eluting Stents Safe After Heart Attack 2Health News:First Unionized Hospital in Texas 2Health News:First Unionized Hospital in Texas 3Health News:You May Be the Key to Cancer Prevention 2Health News:You May Be the Key to Cancer Prevention 3Health News:Key Protein Limits Damage of Heart Attack 2
The ring maintains the bag tension avoiding the development of posterior capsule pleats. It is also established to compensate the efforts induced during the bag retraction....
Mayo dissecting scissors with beveled blades....
Ribbon malleable, general purpose retractor....
The Wire Cutters are designed to cut Kirschner wires up to 2.5 mm diameter easily and smoothly. They are particularly useful for external fixation applications. The Wire Cutters shear fixation wires ...
Medicine Products: